PharmAthene, Inc. (PIP), a biodefense company developing medical countermeasures against biological and chemical threats, Thursday said the U.S. Food and Drug Administration has lifted the clinical hold placed on a proposed Phase II study of SparVax, a next generation recombinant anthrax vaccine.
The clinical hold was enacted in August 2012, prior to the commencement of a proposed Phase II clinical trial of SparVax. In its original notification to the company, the FDA requested that PharmAthene provide additional stability data for its engineering and GMP lots of U.S. manufactured Final Drug Product, as well as additional information about the intended stability indicating assays.
The FDA has now acknowledged in a letter that PharmAthene satisfactorily addressed all its clinical hold issues and that consequently, the clinical hold had been lifted, effective immediately.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.